• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

18F-FDG PET/CT在手术治疗的非小细胞肺癌中的预后价值:一项Meta分析。

Prognostic Value of 18F-FDG PET/CT in Surgical Non-Small Cell Lung Cancer: A Meta-Analysis.

作者信息

Liu Jing, Dong Min, Sun Xiaorong, Li Wenwu, Xing Ligang, Yu Jinming

机构信息

Department of Radiation Oncology and Shandong Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong, China.

Department of Oncology, the People's Hospital of Pingyi County, Pingyi, Shandong, China.

出版信息

PLoS One. 2016 Jan 4;11(1):e0146195. doi: 10.1371/journal.pone.0146195. eCollection 2016.

DOI:10.1371/journal.pone.0146195
PMID:26727114
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4699812/
Abstract

BACKGROUND

The identification of surgical non-small cell lung cancer (NSCLC) patients with poor prognosis is a priority in clinical oncology because of their high 5-year mortality. This meta-analysis explored the prognostic value of maximal standardized uptake value (SUVmax), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) on disease-free survival (DFS) and overall survival (OS) in surgical NSCLC patients.

MATERIALS AND METHODS

MEDLINE, EMBASE and Cochrane Libraries were systematically searched until August 1, 2015. Prospective or retrospective studies that evaluated the prognostic roles of preoperative 18F-FDG PET/CT with complete DFS and OS data in surgical NSCLC patients were included. The impact of SUVmax, MTV or TLG on survival was measured using hazard ratios (HR). Sub-group analyses were performed based on disease stage, pathological classification, surgery only and cut-off values.

RESULTS

Thirty-six studies comprised of 5807 patients were included. The combined HRs for DFS were 2.74 (95%CI 2.33-3.24, unadjusted) and 2.43 (95%CI: 1.76-3.36, adjusted) for SUVmax, 2.27 (95%CI 1.77-2.90, unadjusted) and 2.49 (95%CI 1.23-5.04, adjusted) for MTV, and 2.46 (95%CI 1.91-3.17, unadjusted) and 2.97 (95%CI 1.68-5.28, adjusted) for TLG. The pooled HRs for OS were 2.54 (95%CI 1.86-3.49, unadjusted) and 1.52 (95%CI 1.16-2.00, adjusted) for SUVmax, 2.07 (95%CI 1.16-3.69, unadjusted) and 1.91 (95%CI 1.13-3.22, adjusted) for MTV, and 2.47 (95%CI 1.38-4.43, unadjusted) and 1.94 (95%CI 1.12-3.33, adjusted) for TLG. Begg's test detected publication bias, the trim and fill procedure was performed, and similar HRs were obtained. The prognostic role of SUVmax, MTV and TLG remained similar in the sub-group analyses.

CONCLUSIONS

High values of SUVmax, MTV and TLG predicted a higher risk of recurrence or death in patients with surgical NSCLC. We suggest the use of FDG PET/CT to select patients who are at high risk of disease recurrence or death and may benefit from aggressive treatments.

摘要

背景

由于手术治疗的非小细胞肺癌(NSCLC)患者5年死亡率高,识别预后不良的患者是临床肿瘤学的首要任务。本荟萃分析探讨了最大标准化摄取值(SUVmax)、代谢肿瘤体积(MTV)和总病灶糖酵解(TLG)对手术NSCLC患者无病生存期(DFS)和总生存期(OS)的预后价值。

材料与方法

系统检索MEDLINE、EMBASE和Cochrane图书馆,检索截至2015年8月1日的文献。纳入评估术前18F-FDG PET/CT对手术NSCLC患者预后作用且有完整DFS和OS数据的前瞻性或回顾性研究。使用风险比(HR)衡量SUVmax、MTV或TLG对生存的影响。根据疾病分期、病理分类、单纯手术情况和临界值进行亚组分析。

结果

纳入36项研究,共5807例患者。SUVmax的DFS合并HR分别为2.74(95%CI 2.33-3.24,未调整)和2.43(95%CI:1.76-3.36,调整),MTV分别为2.27(95%CI 1.77-2.90,未调整)和2.49(95%CI 1.23-5.04,调整),TLG分别为2.46(95%CI 1.91-3.17,未调整)和2.97(95%CI 1.68-5.28,调整)。OS的合并HR,SUVmax分别为2.54(95%CI 1.86-3.49,未调整)和1.52(95%CI 1.16-2.00,调整),MTV分别为2.07(95%CI 1.16-3.69,未调整)和1.91(95%CI 1.13-3.22,调整),TLG分别为2.47(95%CI 1.38-4.43,未调整)和1.94(95%CI 1.12-3.33,调整)。Begg检验检测到发表偏倚,进行了剪补法分析,得到了相似的HR。亚组分析中,SUVmax、MTV和TLG的预后作用保持相似。

结论

SUVmax、MTV和TLG值高预示手术NSCLC患者复发或死亡风险更高。我们建议使用FDG PET/CT来选择疾病复发或死亡风险高且可能从积极治疗中获益的患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d48/4699812/69e85d2149f3/pone.0146195.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d48/4699812/4f6427c31e8f/pone.0146195.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d48/4699812/33e02884e54b/pone.0146195.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d48/4699812/48b6bdb5153e/pone.0146195.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d48/4699812/69e85d2149f3/pone.0146195.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d48/4699812/4f6427c31e8f/pone.0146195.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d48/4699812/33e02884e54b/pone.0146195.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d48/4699812/48b6bdb5153e/pone.0146195.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d48/4699812/69e85d2149f3/pone.0146195.g004.jpg

相似文献

1
Prognostic Value of 18F-FDG PET/CT in Surgical Non-Small Cell Lung Cancer: A Meta-Analysis.18F-FDG PET/CT在手术治疗的非小细胞肺癌中的预后价值:一项Meta分析。
PLoS One. 2016 Jan 4;11(1):e0146195. doi: 10.1371/journal.pone.0146195. eCollection 2016.
2
Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.(18)F-FDG PET 代谢肿瘤负荷对非小细胞肺癌手术患者的预后价值。
Acad Radiol. 2013 Jan;20(1):32-40. doi: 10.1016/j.acra.2012.07.002. Epub 2012 Sep 19.
3
Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.采用 FDG PET/CT 测量的容积参数在接受立体定向体部放射治疗的 I 期 NSCLC 患者中的应用:预后价值。
Radiology. 2014 Jan;270(1):275-81. doi: 10.1148/radiol.13130652. Epub 2013 Oct 28.
4
Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer.F-18 FDG PET/CT测量的体积参数在手术切除的非小细胞肺癌中的预后价值
Nucl Med Commun. 2012 Jun;33(6):613-20. doi: 10.1097/MNM.0b013e328351d4f5.
5
Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.(18)F-氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描的基于体积的参数可改善手术切除后早期非小细胞肺癌的预后预测。
Ann Surg. 2013 Feb;257(2):364-70. doi: 10.1097/SLA.0b013e318262a6ec.
6
Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.治疗前 FDG PET/CT 全身总病变糖酵解对非小细胞肺癌的预后价值。
Radiology. 2012 Aug;264(2):559-66. doi: 10.1148/radiol.12111148. Epub 2012 Jun 12.
7
Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.代谢肿瘤负荷 18F-FDG PET 在非手术治疗的非小细胞肺癌患者中的预后价值。
Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):27-38. doi: 10.1007/s00259-011-1934-6. Epub 2011 Sep 23.
8
Whole Body Metabolic Tumor Volume and Total Lesion Glycolysis Predict Survival in Patients with Adrenocortical Carcinoma.全身代谢肿瘤体积和总病灶糖酵解可预测肾上腺皮质癌患者的生存率。
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S714-20. doi: 10.1245/s10434-015-4813-8. Epub 2015 Aug 18.
9
Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer.基于容积的18F-FDG PET/CT评估改善ⅢA-N2期非小细胞肺癌患者的预后预测
AJR Am J Roentgenol. 2015 Sep;205(3):623-8. doi: 10.2214/AJR.14.13847.
10
Prognostic value of the quantitative metabolic volumetric measurement on 18F-FDG PET/CT in Stage IV nonsurgical small-cell lung cancer.18F-FDG PET/CT 定量代谢体积测量在 IV 期非手术小细胞肺癌中的预后价值。
Acad Radiol. 2012 Jan;19(1):69-77. doi: 10.1016/j.acra.2011.08.020.

引用本文的文献

1
Optimizing Pre-Operative Clinical Staging in Resectable Non-Small Cell Lung Cancer (NSCLC): A Retrospective Cohort Study.优化可切除非小细胞肺癌(NSCLC)的术前临床分期:一项回顾性队列研究
Thorac Cancer. 2025 Jun;16(11):e70108. doi: 10.1111/1759-7714.70108.
2
The value of 18F-FDG PET/CT combined with 3D quantitative technology and clinicopathological features in predicting prognosis of NSCLC.18F-FDG PET/CT联合3D定量技术及临床病理特征在预测非小细胞肺癌预后中的价值
Front Oncol. 2025 Apr 8;15:1533569. doi: 10.3389/fonc.2025.1533569. eCollection 2025.
3
Suvmax of the lesion should be considered in the treatment plan for stage I non-small cell lung cancer.

本文引用的文献

1
Survival Prognostic Value of Morphological and Metabolic variables in Patients with Stage I and II Non-Small Cell Lung Cancer.I期和II期非小细胞肺癌患者形态学和代谢变量的生存预后价值
Eur Radiol. 2015 Nov;25(11):3361-7. doi: 10.1007/s00330-015-3754-8. Epub 2015 May 1.
2
Predictive value of 18F-FDG PET and CT morphologic features for recurrence in pathological stage IA non-small cell lung cancer.18F-FDG PET及CT形态学特征对病理ⅠA期非小细胞肺癌复发的预测价值
Medicine (Baltimore). 2015 Jan;94(3):e434. doi: 10.1097/MD.0000000000000434.
3
Differences in the prognostic significance of the SUVmax between patients with resected pulmonary Adenocarcinoma and squamous cell carcinoma.
在I期非小细胞肺癌的治疗方案中应考虑病变的最大标准化摄取值(SUVmax)。
Ann Nucl Med. 2025 Apr 10. doi: 10.1007/s12149-025-02049-0.
4
Mediastinal staging lymph node probability map in non-small cell lung cancer.非小细胞肺癌纵隔分期的淋巴结概率图
Respir Res. 2025 Mar 24;26(1):113. doi: 10.1186/s12931-025-03121-z.
5
Relationship between HE4 levels and metabolic parameters in PET of non-small cell lung cancer patients.非小细胞肺癌患者正电子发射断层显像中HE4水平与代谢参数的关系
Biomark Med. 2025 Apr;19(7):259-265. doi: 10.1080/17520363.2025.2471744. Epub 2025 Mar 1.
6
Preoperative Maximum Standardized Uptake Value Emphasized in Explainable Machine Learning Model for Predicting the Risk of Recurrence in Resected Non-Small Cell Lung Cancer.术前最大标准化摄取值在可解释机器学习模型中得到强调,用于预测切除的非小细胞肺癌复发风险
JCO Clin Cancer Inform. 2025 Mar;9:e2400194. doi: 10.1200/CCI-24-00194. Epub 2025 Mar 5.
7
Is FDG-PET/CT Scan Useful in the Detection of Subcentimeter Mediastinal Lymph Node Involvement in Patients With Lung Carcinoma?氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(FDG-PET/CT)扫描对检测肺癌患者纵隔淋巴结亚厘米转移是否有用?
Cureus. 2024 Nov 27;16(11):e74572. doi: 10.7759/cureus.74572. eCollection 2024 Nov.
8
Predictive value of 18F-FDG PET/CT metabolic parameters for lymph node metastasis of non-small cell lung cancer.18F-FDG PET/CT代谢参数对非小细胞肺癌淋巴结转移的预测价值
Biomark Med. 2025 Jan;19(2):35-41. doi: 10.1080/17520363.2024.2443379. Epub 2024 Dec 24.
9
Prognostic value of metabolic tumor volume on [F]FDG PET/CT in addition to the TNM classification system of locally advanced non-small cell lung cancer.代谢肿瘤体积在[F]FDG PET/CT上对局部晚期非小细胞肺癌的预后价值(除TNM分类系统外)
Cancer Imaging. 2024 Dec 21;24(1):171. doi: 10.1186/s40644-024-00811-7.
10
[Advances in the Application of Adjuvant Chemotherapy and Targeted Therapy 
in Postoperative Patients with Stage I Lung Adenocarcinoma].[辅助化疗和靶向治疗在Ⅰ期肺腺癌术后患者中的应用进展]
Zhongguo Fei Ai Za Zhi. 2024 Oct 20;27(10):777-784. doi: 10.3779/j.issn.1009-3419.2024.101.26.
肺腺癌和肺鳞癌切除患者之间SUVmax预后意义的差异。
Asian Pac J Cancer Prev. 2014;15(23):10171-4. doi: 10.7314/apjcp.2014.15.23.10171.
4
Prognostic value of total lesion glycolysis by 18F-FDG PET/CT in surgically resected stage IA non-small cell lung cancer.18F-FDG PET/CT 总肿瘤糖酵解对手术切除的ⅠA 期非小细胞肺癌的预后价值。
J Nucl Med. 2015 Jan;56(1):45-9. doi: 10.2967/jnumed.114.147561. Epub 2014 Dec 18.
5
Difference in prognostic values of maximal standardized uptake value on fluorodeoxyglucose-positron emission tomography and cyclooxygenase-2 expression between lung adenocarcinoma and squamous cell carcinoma.肺腺癌与肺鳞状细胞癌在氟脱氧葡萄糖-正电子发射断层扫描中最大标准化摄取值及环氧化酶-2表达的预后价值差异。
World J Surg Oncol. 2014 Nov 13;12:343. doi: 10.1186/1477-7819-12-343.
6
Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.18F-FDG PET/CT检查中SUVmax及代谢肿瘤体积对无淋巴结转移的早期非小细胞肺癌患者的预后价值
Biomed Mater Eng. 2014;24(6):3091-103. doi: 10.3233/BME-141131.
7
Prognostic value of volumetric parameters of (18)F-FDG PET in non-small-cell lung cancer: a meta-analysis.(18)F-FDG PET 容积参数对非小细胞肺癌的预后价值:一项荟萃分析。
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):241-51. doi: 10.1007/s00259-014-2903-7. Epub 2014 Sep 6.
8
Survival outcome after stereotactic body radiation therapy and surgery for stage I non-small cell lung cancer: a meta-analysis.立体定向体部放射治疗和手术治疗Ⅰ期非小细胞肺癌后的生存结果:一项荟萃分析。
Int J Radiat Oncol Biol Phys. 2014 Nov 1;90(3):603-11. doi: 10.1016/j.ijrobp.2014.05.055. Epub 2014 Jul 19.
9
Visual versus quantitative assessment of intratumor 18F-FDG PET uptake heterogeneity: prognostic value in non-small cell lung cancer.肿瘤内 18F-FDG PET 摄取异质性的视觉与定量评估:非小细胞肺癌的预后价值。
J Nucl Med. 2014 Aug;55(8):1235-41. doi: 10.2967/jnumed.113.133389. Epub 2014 Jun 5.
10
Intratumoral Metabolic Heterogeneity for Prediction of Disease Progression After Concurrent Chemoradiotherapy in Patients with Inoperable Stage III Non-Small-Cell Lung Cancer.瘤内代谢异质性对不可切除的Ⅲ期非小细胞肺癌患者同步放化疗后疾病进展的预测作用
Nucl Med Mol Imaging. 2014 Mar;48(1):16-25. doi: 10.1007/s13139-013-0231-7. Epub 2013 Sep 6.